BSc3094 is a Tau aggregation inhibitor. BSc3094 can be used for the research of Alzheimer's disease (AD) In Vivo BSc3094 (3 mg/kg; i.v.) direct intraventricular administration reduces sarkosyl-insoluble Tau . BSc3094 (0.075~1.5 mM; intraventricular administration) reduces the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70% . BSc3094 reverses the pre-synaptic impairment in organotypic hippocampal slices from pro-aggregant mice, by reversing the pairedpulse depression observed in non-treated pro-aggregant Tau slices after applying a paired-pulse stimulus of the Schaffer collaterals. BSc3094 reverses the increase in Tau phosphorylation levels in rTg4510 mice down to control level. BSc3094 partially reversed the memory deficits in rTg4510 mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice Dosage: 3 mg/kg Administration: I.v. Result: Direct intraventricular administration reduced sarkosyl-insoluble Tau. Animal Model: rTg4510 mice Dosage: 0.075~1.5 mM Administration: Intraventricular administration Result: Reduced the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70%. Form:Solid IC50& Target:Tau aggregation